So I saw this on Sunrise some time back and now they're doing a cap raise...
"Opportunity to pre-register for the upcoming QBiotics Offer
From the desk of Victoria Gordon, CEO of QBiotics Limited
Thankyou for expressing interest in our company. QBiotics Limited is the owner of anti-cancer drug EBC-46 which has been the subject of recent media attention on A Current Affair and also Sunrise (Seven) for its success in treating solid tumours in pets.
QBiotics Limited, a wholly owned subsidiary of EcoBiotics Limited, is focused on developing EBC-46 through to commercialisation in the human and veterinary markets globally. Preperations for Human Trials have commenced.
We now invite you to pre-register for the upcoming QBiotics Limited offer. By pre-registering you will be kept up to date with the upcoming capital raising, as well as general updates from the company as they are made public.
Cancer - a Global Problem:
The American Cancer Society estimated that globally more than 12 million people will be diagnosed with cancer and 7.6 million will die of cancer this year. That's about 20,000 deaths per day. In Australia more than 43,000 people are expected to die from cancer in 2010. An estimated 114,000 new cases of cancer will be diagnosed in Australia in 2010.
About QBiotics and EBC-46:
From deep within the tropical rainforests of North Queensland, we have found a new generation drug we have named EBC-46. The results of veterinary trials on inoperable tumours support the potential of this drug in the global multi-billion dollar human and veterinary markets.
QBiotics has developed EBC-46 from conception. The IP rights are unencumbered and the patent is pending for use in Australia, New Zealand, USA, Canada, India, China, Japan and Europe.
The drug has proven to be strongly efficacious during Veterinary Trials successfully treating a range of spontaneous tumours in over 100 dogs, cats and horses.
Results to date have been encouraging (click here to view case studies) with the total disintegration of tumours, together with rapid healing and no adverse side effects. Preparation for Clinical Phase I trials in humans have commenced and these trials are expected to begin early 2011."